TMC launches co-hosted health tech accelerator with Denmark

biobridge support

A new program established at TMC in partnership with Denmark will support the growth of three health tech companies. Photo courtesy of TMC

Years ago, the Texas Medical Center established a biobridge to exchange technology and support with Denmark. Now, the two organizations are coming together to advance three health tech startups through a unique accelerator.

TMC and Denmark-based BioInnovation Institute announced today that three companies from BII will join a customized accelerator program that will guide them toward a United States go-to-market strategy. The program will be built off of the TMCi Health Tech Accelerator program.

“At TMC, we are elevating our ability to create curated go-to-market experiences for hand-selected companies that have a relationship with our partners at the BioInnovation Institute and that are seeking to prepare for of market expansion in the U.S.,” says Emily Reiser, associate director of TMC Innovation, in a news release. “We are excited about the opportunity to collaborate with BII and these founders.”

The three startups will head to Houston next week and incubate for six months, working with TMCi advisers and mentors on their individual challenges within commercialization and U.S. expansion. The three companies in the program are:

  • Aiomic, which is developing Aiomic360, an AI platform for postoperative complications. "With automated tracking and real-time risk assessment, Aiomic360 will function as a quality management tool for hospitals, a decision support tool for healthcare practitioners, and an individualized patient empowerment tool for surgical candidates," per the release.
  • Also tapping into AI, Orbit Health's solution, Neptune, is using motion data from smartwatches to track Parkinson’s motor state and treatment response passively. "Its continuous and objective insights enable regular treatment personalization that is needed throughout the course of the disease to optimize patient outcomes and improve quality of life," reads the release.
  • HEI Therapeutics is enabling at-home hypothyroidism management. "The innovative solution includes a patented finger stick blood test and digital patient empowerment tools and aims to significantly reduce the share of patients that is poorly regulated with medication," according to the release.

The TMC and the Ministry of Foreign Affairs of Denmark launched the Biobridge in 2019. BII is a nonprofit organization with a few resources — the Bio Studio, Venture Lab, and Venture House — that support life science startups with resources and even funding of up to €3 million per projects and €1.8 million per company.

“As we strengthen our offering to support visionary healthcare innovators to develop products and solutions to address clear unmet needs, our partnership with Texas Medical Center allows BII startups to gain exposure to US market and ready themselves for US market entry. We are thrilled about this collaboration with the Texas Medical Center which is one of the largest life science ecosystems in the world,” says Tony Cheng-fu Chang, principal at BioInnovation Institute. “Through the customized accelerator program, these three healthcare startups will acquire critical insight to create field-ready plans for bringing their products and solutions to the US market.”

From Your Site Articles
Optellum, based in the TMC Innovation Institute, has entered into a partnership with Johnson & Johnson. Photo via Getty Images

AI-optimized health startup with HQ in Houston takes its tech to the next level with new partner

ending cancer

Optellum, a startup whose technology helps doctors detect and treat lung cancer, has teamed up with one of the world's health care giants to broaden the software's reach.

On August 18, Optellum — whose U.S. headquarters is at Houston's TMC Innovation Institute — unveiled its new collaboration with the Lung Care Initiative at Johnson & Johnson, which racked up global sales of $82.6 billion last year. Optellum's key contribution to the partnership is its AI-powered software that aids medical professionals in detecting and treating patients with lung cancer.

With Optellum's AI-powered lung cancer diagnostics now being included in J&J's Lung Cancer Initiative, medical teams soon will enjoy access to an array of complementary technologies designed to improve diagnosis and treatment of early stage cancer. The Lung Cancer Initiative, launched in 2018 by J&J and Boston University, aims to prevent, detect, and cure lung cancer.

Lung cancer ranks as the world's most common type of cancer and leading cause of cancer deaths. About 1.8 million people around the world die from lung cancer each year. The current five-year survival rate is just 20 percent, primarily due to most patients being diagnosed after the disease has reached an advanced stage.

Optellum's Virtual Nodule Clinic software received clearance from the U.S. Food and Drug Administration (FDA) in March. Hospitals in the U.S. are rolling out the technology, with Asia-Pacific and European hospitals on track to eventually adopt the software.

The Optellum platform identifies and tracks at-risk patients, and assigns a "lung cancer prediction" score to lung nodules — small lesions, frequently detected in chest CT scans, that may or may not be cancerous.

"Optellum's vision is to redefine the early intervention of lung cancer by enabling every patient to be diagnosed and treated at the earliest possible stage, when the chances of cure are highest," the United Kingdom-based company says in a news release.

The startup — a 2019 graduate of the Texas Medical Center's accelerator — hopes to apply the technology to other lung diseases, such as chronic obstructive pulmonary disease (COPD).

Optellum recently was named one of the 101 best medical device startups in the United Kingdom. In June, the startup was among 38 AI projects chosen by the UK Department of Health and Social Care to participate in a roughly $50 million health care initiative.

Václav Potěšil, founder and CEO of Optellum, says the Johnson & Johnson collaboration represents a "significant milestone" for his company.

The J&J partnership "brings us one step closer to Optellum's vision of redefining early lung cancer treatment by helping every clinician in every hospital to make the right decisions and provide their patients the best chance to fight back," Potěšil says.

Of the 35 people employed by Optellum, three are based in the U.S. and the rest in the United Kingdom. The company's team also includes several part-time consultants, most of whom are based in the U.S. By the end of this year, Optellum plans to expand its U.S. team with several full-time hires, including a senior executive located in Houston.

Beginning next year in Houston, Optellum expects its technology to be available for patients in clinical settings.

For Potěšil, Optellum's mission is personal. He lost an aunt to lung cancer within a year of her Stage 4 diagnosis.

"I've seen firsthand how very healthy people can be killed, and it's still the most common and deadliest cancer worldwide," Potěšil is quoted as saying by the Texas Medical Center. "We are really focused on enabling cancer patients to be diagnosed at the earliest possible stage and be cured. It's not just the modeled data on the computer. It's addressing the right clinical problems to add value to doctors."

Don't miss these informative online events happening throughout the month of May. Photo by Getty Images

10+ can't-miss Houston business and innovation events online in May

Where to be online

This month, Houstonians have yet another good batch of online innovation events — from Zoom panels to virtual conferences — and you and your tech network need to know about them.

Here's a roundup of virtual events not to miss this month — like Houston Tech Rodeo, a virtual showcase from Rice University's data science students, and more.

Note: This post might be updated to add more events.

May 4 — Perfecting Your Pitch

Join The Ion for our series with DeckLaunch and Fresh Tech Solutionz as they discuss the importance and value of your pitch deck when reaching your target audience.

The event is on Tuesday, May 4, at 1 pm. It's free and can be accessed online. Click here to register.

May 5 — D2K Virtual Showcase - Spring 2021

Join Rice University online for the interactive D2K Showcase. Student teams from the D2K Capstone and other data science programs will showcase their data science work and compete for prizes.

The event is on Wednesday, May 5, at 5 pm. It's free and can be accessed online. Click here to register.

May 6 — Carbon to Value Initiative Kickoff

Kick off a new accelerator dedicated to carbontech. The Carbon to Value (C2V) Initiative is a multi-year collaboration between The Urban Future Lab, Greentown Labs, and the Fraunhofer USA TechBridge Program. Welcome the first cohort of startups to this exciting new program, which includes Houston-based Cemvita Factory.

The event is on Thursday, May 6, at 3 pm. It's free and can be accessed online. Click here to register.

May 12 — Enventure "Inspire" Seminar Series - With Dr. Reece Norris

The "Inspire" Seminar Series was developed by Enventure to help students learn about the reality of working in the biotech and biomedical fields. This particular event will star Mr. Reece Norris, JD, co-founder and COO of WeInfuse. Reece began his career in corporate law and eventually entered the provider-based infusion center market, where he went on to create a first-of-its-kind infusion delivery business model.

The event is on Wednesday, May 12, at 6 pm. It's free and can be accessed online. Click here to register.

MAy 13 — Changing the Colors of Investment

Maria Maso of the Business Angel Minority Association and Stephanie Tsuru of SheSpace are planning an inspiring conversation on diversity in investment.

The event is on Thursday, May 13, at 11:30 am. It's free and can be accessed online. Click here to register.

May 14 — Investor Speaker Series: Navigating Corporate Venture Capital

Greentown Labs is putting on a virtual event about Corporate Venture Capital. CVCs have played an important role in advancing climatetech in general, and supporting the Greentown ecosystem specifically. In this conversation, we will connect with CVCs within the Greentown network—and representing diverse industries—to discuss what they look for in startups, how they work with startups, how they like to participate in deals, and their perspective on key trends in climatetech investing. Panelists include:

The event is on Friday, May 14, at 11 am. It's free and can be accessed online. Click here to register.

May 17-23 — Houston Tech Rodeo

The Houston Tech Rodeo — a festival of events put on both online and in person — celebrates the convergence of popular culture and innovation in Houston and has transformed into an essential destination for founders and talented individuals to spur new connections and ideas while highlighting all that Houston has to offer.

The round-up of events takes place May 17 to 23. Check out all the events and register by clicking here.

May 18 — Accessibility in Tech presented by Microsoft

Attendees at this event presented by Capital Factory can look forward to a keynote chat from a serial entrepreneur or investor, insightful discussion sessions, a startup showcase pitch competition, multiple future of accessibility breakout sessions, and panels on accessibility in design and accessibility in hiring and human resource management.

The event is on Tuesday, May 18, at noon. It's free and can be accessed online. Click here to register.

May 20 — Future of Patient Experience

Healthcare centered around the patient's experience is becoming a bigger priority for systems around the world. Join experts from Houston, Texas Medical Center, the UK, and Denmark for a Biobridge event. Healthcare centered around the patient's experience is becoming a bigger priority for systems around the world.

The event is on Thursday, May 20, at 9 am. It's free and can be accessed online. Click here to register.

May 25 — Industrial XR Forum: Enterprise Projects & Tech Roundup

The Industrial XR Forum is hosting an industry-wide event focused specifically on industrial/energy and engineering large enterprise and rapidly scaling immersive tech program leaders to gain insights, use cases and technology needed for their large and often global VR/AR/XR, 3D, Digital Twin and Spatial Computing projects.


The event is on Tuesday, May 25, at 10 am. It's free and can be accessed online. Click here to register.

May 25 — HYP Referral Networking: Building Stronger Relationships

Join the Houston Young Professionals and General Assembly for a virtual networking event.

The event is on Tuesday, May 25, at 11:45 am. It's free and can be accessed online. Click here to register.

May 25 — HALO Presents: Ongoing Changes in Consumer Behavior as a Result of Covid-19

The COVID-19 pandemic caused a significant shift in consumer behavior as cities around the world saw shut downs and restrictions. Every aspect of life was affected. As the the country reopens and we enter our new normal what trends from the pandemic will stick around and what will change? Join the Texas HALO Fund and some of its portfolio companies operating in the consumer space to hear their experiences of the pandemic first hand.

The event is on Tuesday, May 25, at 5 pm. It's free and can be accessed online. Click here to register.

May 26 — Houston Startup Showcase Semifinals

Four semifinalists will come together on the virtual stage and compete for a chance to move on to the The Ion's Startup Showcase Finals. Watch the four startups pitch their company and see who the judges will select to move on to the Final and have the opportunity to compete for a prize package. The presenting companies are:

The event is on Wednesday, May 26, at 6 pm. It's free and can be accessed online. Click here to register.

Houston-based PolyVascular has invented a polymer-based heart valve for children with congenital heart disease. Photo courtesy of TMC Innovation

Houston startup with life-saving innovation receives $2M grant

for the children

A $2 million federal grant will enable Houston-based PolyVascular to launch human trials of what it hails as the first polymer-based heart valve for children.

In conjunction with the grant, Dr. Will Clifton has joined the medical device company as chief operating officer. He will oversee the grant as principal investigator, and will manage the company's operations and R&D. Clifton is president and co-founder of Houston-based Enventure, a medical innovation incubator and education hub. He previously was senior director of medical affairs at Houston-based Procyrion, a clinical-stage medical device company.

PolyVascular's Phase II grant came from the Small Business Innovation Research (SBIR) program, which promotes technological projects.

The PolyVascular heart valve will help treat congenital heart disease affecting more than 1 million around the world. PolyVascular plans to launch clinical trials of the valve in children 5 and over within two years.

"Congenital heart disease remains the most common category of birth defect and a leading cause of childhood death in the developed world," reads a March 30 news release from PolyVascular, founded in 2014.

PolyVascular says the valve can be implanted without surgery, and can avoid the use of valve replacements from humans or animals. Those valve replacements are difficult to find and often don't last too long, leading to frequent follow-up surgeries.

"Our aim at PolyVascular is to transform the care of children with congenital heart disease by developing an entirely new generation of valves made of medical-grade polymer devoid of any biological tissue," Dr. Henri Justino, chief medical officer at PolyVascular, says in a release. "The valves in use so far for children have been made of biological tissue. Unfortunately, our immune systems target and destroy this biological tissue, sometimes rapidly, rendering the valve ineffective."

The SBIR grant isn't the only win for PolyVascular in recent years.

In 2019, the startup came away with several honors in the 2019 Texas A&M New Ventures Competition. It won the pitch competition (complete with a $5,000 cash award), and received the Biotex Investment Prize, Amerra Visualization Services Prize, and GOOSE Society Investment Prize.

Also in 2019, PolyVascular, a member of TMCx's 2017 medical device cohort, won in the medical device and health disparities and equity categories at the fifth annual Impact Pediatric Health pitch competition. Additionally, the Southwest National Pediatric Device Consortium granted the company up to $25,000.

Last year, MedTech Innovator, a nonprofit accelerator in the medical technology sector, announced PolyVascular was one of 50 companies chosen to participate in the organization's flagship four-month accelerator program.

"During these uncertain and challenging times, the need for health innovations — specifically those that promise to deliver long-term value to the health care system and patients — is more critical than ever," said Paul Grand, CEO of MedTech Innovator.

Another Houston startup, Vivante Health, also was picked for the MedTech Innovator program. Vivante is a digital health company that helps people address digestive health and wellness.

The Texas Medical Center's Innovation Institute named 15 Texas companies to its new cancer-focused accelerator program. Photo courtesy of TMCx

TMC cancer therapeutic accelerator names inaugural cohort

cancer innovation

The Texas Medical Center named 15 groundbreaking researchers and companies to its inaugural class of the Accelerator for Cancer Therapeutics on Thursday. All hail from the Lone Star State.

The ACT program is the only accelerator focused on cancer treatment at the earliest stages of commercialization, thanks to a $5 million grant from the Cancer Prevention and Research Institute of Texas awarded to the TMC in the fall of 2019.

The nine-month program kicked-off at the end of January and will be run by TMC Innovation, according to a release from the TMC. It aims to provide the class with resources to help their oncology biotech projects reach new milestones, including even commercialization.

The inaugural cohort is made up of companies and researchers exploring immunotherapy, cell therapy, targeted therapy, cancer pain, and drug platforms. The group is split about evenly between companies and academic researchers. The group of Texans includes:

  • Raptamer Discovery Group
  • IDA Therapeutics
  • Elbrus Therapeutics
  • Parthenon Therapeutics
  • Lokesh Battula
  • Aumeta
  • Autoimmunity Biologic Solutions
  • Max Mamonkin
  • Qing Yi
  • Astero Alta
  • TEZCAT Laboratories
  • Anil Sood
  • Coactigon
  • Xiadong Cheng
  • IonTx

At the end of the nine months, the class will present an integrated strategic plan and at least one grant submission. They will also have the opportunity to pitch investors and corporations.

The class will also gain support in grant writing, chemistry, and funding opportunities, as well as mentorship.

"As the past year has shown, the pace of scientific discovery can be blistering," says Tom Luby, director of TMC Innovation. "At the same time, successfully translating research into effective therapies available to patients requires a mix of business, technical and regulatory skills that may not typically be available to researchers.

"By linking the participants with mentors who can both advance their scientific work and support the technical needs, we expect this first class of ACT participants will make a meaningful difference for cancer patients in Texas and beyond."

TMCx, which is also run by TMC Innovation, recently announced seven health tech companies that were selected to its 2021 class of its health tech accelerator.

Broader in scope that the ACT accelerator, the TMCx startups focus on an array of subject matters from heart health to artificial intelligence to extremity rehabilitation.

After a virtual bootcamp, the TMCx team selected seven startups to move forward in the accelerator. Photo courtesy of TMC

These are the 7 newest health tech companies to join TMCx

new to hou

Last year, TMCx, the Texas Medical Center's health tech startup accelerator pivoted to digital programming.

The accelerator revamped its program to allow for an initial Bootcamp stage that would bring in a larger group of startups and then, after the boot camp, the program would move forward with a smaller group through the official acceleration process.

"We hosted 21 companies, representing six countries and 10 states, who each engaged with subject matter experts, clinical leaders, and corporate partners," writes Emily Reiser, senior manager of Innovation Community Engagement at TMC Innovation, in a blog post. "Over half of which ended Bootcamp in advanced discussions with hospitals and/or corporate partners."

Through the bootcamp, TMCx has accepted seven startups into the program. These companies are currently engaged with the TMC community and are receiving support, mentorship, and other opportunities.

Cardiosense

Image via cardiosense.com

Chicago-based Cardiosense, a medical device company with heart health tracking technology, is familiar with Houston innovation. The company won sixth place in the 2020 Rice Business Plan Competition, and the TMC's prize at the event.

Cognetivity Neurosciences

Image via Getty Images

Cognetivity Neurosciences, founded in the United Kingdom, is a digital health platform that taps into neuroscience and artificial intelligence to measure cognitive performance of patients in order to more effectively allow for early detection and management of neurodegenerative disorders.

Eleos Health

Image via eleos.health

Cambridge, Massachusetts-based Eleos Health is focused on helping behavioral health clinicians to optimize their efforts with an all-in-one behavioral health platform. It combines telehealth, measurement-based, and evidence-based care in one holistic solution, and is powered by therapy-specific voice analysis and natural language processing.

Harmonic Bionics

Image via harmonicbionics.com

Harmonic Bionics is one of two Lone Star State companies in the program. The Austin-based robotics startup is working on technology that can help improve upper extremity rehabilitation for patients.

Native Cardio

Photo via Getty Images

Florida-based Native Cardio is tapping into technology to help find a solution to postoperative atrial fibrillation (POAF), which is the most frequent complication after cardiac surgery, occurring in up to 60 percent of patients, according to the company's website. The goal is to help reduce costs, increase accessibility, and improve quality of care.

Progenerative Medical

Image via progenerative.com

Progenerative Medical, based in San Antonio, is working on a clinically-proven reduced pressure therapy to spinal and orthopedic indications to significantly improve clinical outcomes.

RCE Technologies

Image via rce.ai

Atlanta-based RCE Technologies is an artificial intelligence-enabled medical device company that has created a technology that can detect heart attacks early using non-invasive wearables.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston robotics co. unveils new robot that can handle extreme temperatures

Hot New Robot

Houston- and Boston-based Square Robot Inc.'s newest tank inspection robot is commercially available and certified to operate at extreme temperatures.

The new robot, known as the SR-3HT, can operate from 14°F to 131°F, representing a broader temperature range than previous models in the company's portfolio. According to the company, its previous temperature range reached 32°F to 104°F.

The new robot has received the NEC/CEC Class I Division 2 (C1D2) certification from FM Approvals, allowing it to operate safely in hazardous locations and to perform on-stream inspections of aboveground storage tanks containing products stored at elevated temperatures.

“Our engineering team developed the SR-3HT in response to significant client demand in both the U.S. and international markets. We frequently encounter higher temperatures due to both elevated process temperatures and high ambient temperatures, especially in the hotter regions of the world, such as the Middle East," David Lamont, CEO of Square Robot, said in a news release. "The SR-3HT employs both active and passive cooling technology, greatly expanding our operating envelope. A great job done (again) by our engineers delivering world-leading technology in record time.”

The company's SR-3 submersible robot and Side Launcher received certifications earlier this year. They became commercially available in 2023, after completing initial milestone testing in partnership with ExxonMobil, according to Square Robot.

The company closed a $13 million series B round in December, which it said it would put toward international expansion in Europe and the Middle East.

Square Robot launched its Houston office in 2019. Its autonomous, submersible robots are used for storage tank inspections and eliminate the need for humans to enter dangerous and toxic environments.

---

This article originally appeared on EnergyCapitalHTX.com.

Houston's Ion District to expand with new research and tech space, The Arc

coming soon

Houston's Ion District is set to expand with the addition of a nearly 200,000-square-foot research and technology facility, The Arc at the Ion District.

Rice Real Estate Company and Lincoln Property Company are expected to break ground on the state-of-the-art facility in Q2 2026 with a completion target set for Q1 2028, according to a news release.

Rice University, the new facility's lead tenant, will occupy almost 30,000 square feet of office and lab space in The Arc, which will share a plaza with the Ion and is intended to "extend the district’s success as a hub for innovative ideas and collaboration." Rice research at The Arc will focus on energy, artificial intelligence, data science, robotics and computational engineering, according to the release.

“The Arc will offer Rice the opportunity to deepen its commitment to fostering world-changing innovation by bringing our leading minds and breakthrough discoveries into direct engagement with Houston’s thriving entrepreneurial ecosystem,” Rice President Reginald DesRoches said in the release. “Working side by side with industry experts and actual end users at the Ion District uniquely positions our faculty and students to form partnerships and collaborations that might not be possible elsewhere.”

Developers of the project are targeting LEED Gold certification by incorporating smart building automation and energy-saving features into The Arc's design. Tenants will have the opportunity to lease flexible floor plans ranging from 28,000 to 31,000 square feet with 15-foot-high ceilings. The property will also feature a gym, an amenity lounge, conference and meeting spaces, outdoor plazas, underground parking and on-site retail and dining.

Preleasing has begun for organizations interested in joining Rice in the building.

“The Arc at the Ion District will be more than a building—it will be a catalyst for the partnerships, innovations and discoveries that will define Houston’s future in science and technology,” Ken Jett, president of Rice Real Estate Company, added in the release. “By expanding our urban innovation ecosystem, The Arc will attract leading organizations and talent to Houston, further strengthening our city’s position as a hub for scientific and entrepreneurial progress.”

Intel Corp. and Rice University sign research access agreement

innovation access

Rice University’s Office of Technology Transfer has signed a subscription agreement with California-based Intel Corp., giving the global company access to Rice’s research portfolio and the opportunity to license select patented innovations.

“By partnering with Intel, we are creating opportunities for our research to make a tangible impact in the technology sector,” Patricia Stepp, assistant vice president for technology transfer, said in a news release.

Intel will pay Rice an annual subscription fee to secure the option to evaluate specified Rice-patented technologies, according to the agreement. If Intel chooses to exercise its option rights, it can obtain a license for each selected technology at a fee.

Rice has been a hub for innovation and technology with initiatives like the Rice Biotech Launch Pad, an accelerator focused on expediting the translation of the university’s health and medical technology; RBL LLC, a biotech venture studio in the Texas Medical Center’s Helix Park dedicated to commercializing lifesaving medical technologies from the Launch Pad; and Rice Nexus, an AI-focused "innovation factory" at the Ion.

The university has also inked partnerships with other tech giants in recent months. Rice's OpenStax, a provider of affordable instructional technologies and one of the world’s largest publishers of open educational resources, partnered with Microsoft this summer. Google Public Sector has also teamed up with Rice to launch the Rice AI Venture Accelerator, or RAVA.

“This agreement exemplifies Rice University’s dedication to fostering innovation and accelerating the commercialization of groundbreaking research,” Stepp added in the news release.

View All Listings